Evidence map›Paper›PMID 35328661›Full record

ArticleInternational journal of molecular sciences2022

A Modular Composite Device of Poly(Ethylene Oxide)/Poly(Butylene Terephthalate) (PEOT/PBT) Nanofibers and Gelatin as a Dual Drug Delivery System for Local Therapy of Soft Tissue Tumors.

Anna Liguori, Alessandro De Vita, Giulia Rossi, Luisa Stella Dolci, Silvia Panzavolta, Chiara Gualandi, Laura Mercatali, Toni Ibrahim, Maria Letizia Focarete

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Gelatin-based anticancer drug delivery nanosystems: A mini review.Frontiers in bioengineering and biotechnology · 2023
    Review
  8. Review
  9. Article
  10. The emerging role of cancer nanotechnology in the panorama of sarcoma.Frontiers in bioengineering and biotechnology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Anna LiguoriDepartment of Chemistry "Giacomo Ciamician" and INSTM UdR of Bologna, University of Bologna, Via Selmi 2, 40126 Bologna, Italy.
Alessandro De VitaOsteoncology Unit, Bioscience Laboratory, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.ORCID 0000-0002-1677-5797
Giulia RossiDepartment of Chemistry "Giacomo Ciamician" and INSTM UdR of Bologna, University of Bologna, Via Selmi 2, 40126 Bologna, Italy.
Luisa Stella DolciDepartment of Pharmacy and BioTechnology, University of Bologna, Via S. Donato 19/2, 40127 Bologna, Italy.
Silvia PanzavoltaDepartment of Chemistry "Giacomo Ciamician" and INSTM UdR of Bologna, University of Bologna, Via Selmi 2, 40126 Bologna, Italy.
Chiara GualandiDepartment of Chemistry "Giacomo Ciamician" and INSTM UdR of Bologna, University of Bologna, Via Selmi 2, 40126 Bologna, Italy.ORCID 0000-0002-2020-1892
Laura MercataliOsteoncology Unit, Bioscience Laboratory, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
Toni IbrahimOsteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.ORCID 0000-0003-0259-4167
Maria Letizia FocareteDepartment of Chemistry "Giacomo Ciamician" and INSTM UdR of Bologna, University of Bologna, Via Selmi 2, 40126 Bologna, Italy.ORCID 0000-0002-0458-7836
University of Bologna · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITIstituto Ortopedico Rizzoli · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the clinical management of solid tumors, the possibility to successfully couple the regeneration of injured tissues with the elimination of residual tumor cells left after surgery could open doors to new therapeutic strategies. In this work, we present a composite hydrogel-electrospun nanofiber scaffold, showing a modular architecture for the delivery of two pharmaceutics with distinct release profiles, that is potentially suitable for local therapy and post-surgical treatment of solid soft tumors. The composite was obtained by coupling gelatin hydrogels to poly(ethylene oxide)/poly(butylene terephthalate) block copolymer nanofibers. Results of the scaffolds' characterization, together with the analysis of gelatin and drug release kinetics, displayed the possibility to modulate the device architecture to control the release kinetics of the drugs, also providing evidence of their activity. In vitro analyses were also performed using a human epithelioid sarcoma cell line. Furthermore, publicly available expression datasets were interrogated. Confocal imaging showcased the nontoxicity of these devices in vitro. ELISA assays confirmed a modulation of IL-10 inflammation-related cytokine supporting the role of this device in tissue repair. In silico analysis confirmed the role of IL-10 in solid tumors including 262 patients affected by sarcoma as a negative prognostic marker for overall survival. In conclusion, the developed modular composite device may provide a key-enabling technology for the treatment of soft tissue sarcoma.

Indexed as

NanofibersSoft Tissue NeoplasmsAlkenesDrug Delivery SystemsEthylene OxideGelatinHumansHydrogelsInterleukin-10OxidesPhthalic AcidsPolyestersPolyethylene GlycolsPolyethylene TerephthalatesTissue EngineeringTissue ScaffoldsAlkenesbutyleneEthylene OxideGelatinHydrogelsInterleukin-10OxidesPhthalic AcidsPolyestersPolyethylene GlycolsPolyethylene Terephthalatesterephthalic acidchemotherapycomposite scaffolddual-drug delivery systemselectrospinninggelatinhydrogelPEOT/PBTregenerative medicinesarcoma

Identifiers

PMID35328661
PMCPMC8948985
OpenAlexW4221078603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.